Skip to main content
52°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bicycle Therapeutics plc
< Previous
1
2
Next >
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
March 28, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
January 11, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
January 04, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
October 10, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
September 19, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
September 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
August 02, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
June 08, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
May 26, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 11, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
April 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
January 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
November 09, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 04, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
November 04, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer
November 02, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
October 26, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 18, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Tickers
BCYC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.